P2-PANC-G0633Active studySynthetic mock data
Neoadjuvant cytotoxic + immunomodulator window-of-opportunity
Pathologic complete response
Phase
II
Enrollment
41/90
46%
Sites
6
Readout
TBD
Waterfall — best % change in target-lesion sum (P2-PANC-G0633)
Per-subject best response from baseline. Sorted descending. Reference lines at PR (-30%) and PD (+20%) thresholds.
CR (0)PR (3)SD (1)PD (0)
4 subjects, sorted by best responseDrill into study →
Protocol summary
- Sponsor
- Vanq Surgical Oncology Group
- Status
- paused
- Start date
- 2024-12-01
- Arms
- 2
- Sites
- 6
- Primary endpoint
- Pathologic complete response
Endpoints assigned to this study
Subjects in P2-PANC-G0633
4 subjects with serial RECIST measurements
Featured subject
Antonio Bianchi · s-0633-019 · MRN 6027719
RECIST 1.1 — Target lesions
Serial measurements (mm) and per-visit response
Sum-of-diameters; % from baseline (PR ≤ -30%); % from nadir (PD ≥ +20% absolute ≥ 5 mm)
| Lesion | Modality | Pre-tx2025-08-15 | Pre-op2025-10-10 | Post-op2025-11-21 | Wk 242026-01-30 |
|---|---|---|---|---|---|
Pancreas head | CT | 28 | 22 | 18 | 16 |
| Sum of diameters | mm | 28 | 22 | 18 | 16 |
| % from baseline | 0.0% | -21.4% | -35.7% | -42.9% | |
| % from nadir | 0.0% | 0.0% | 0.0% | 0.0% | |
| RECIST response | NE | PR | PR | PR |
Non-target lesions
Per-visit qualitative status (presence / absence / equivocal / new)
| Lesion | Pre-tx | Pre-op | Post-op | Wk 24 |
|---|
Cohorts in P2-PANC-G0633
Cross-links